A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Public ClinicalTrials.gov record NCT00569582. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome
Study identification
- NCT ID
- NCT00569582
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Corcept Therapeutics
- Industry
- Enrollment
- 50 participants
Conditions and interventions
Conditions
Interventions
- mifepristone Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2007
- Primary completion
- Dec 31, 2010
- Completion
- Not listed
- Last update posted
- Aug 21, 2013
Started 2007
United States locations
- U.S. sites
- 17
- U.S. states
- 14
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham School of Medicine | Birmingham | Alabama | 35294 | — |
| AMCR Institute Inc. | Escondido | California | 92026 | — |
| Stanford University Medical Center | Stanford | California | 94305-5826 | — |
| The Center for Diabetes and Endocrine Care | Hollywood | Florida | 33021 | — |
| Northwestern University Feinberg Medical; Division of Endocrinology, Metabolism & Molecular Medicine | Chicago | Illinois | 60611 | — |
| The University of Chicago | Chicago | Illinois | 60637 | — |
| Sinai Hospital of Baltimore | Baltimore | Maryland | 21215 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| University of Michigan Medical Center | Ann Arbor | Michigan | 48109 | — |
| University of Mississippi Medical Center | Jackson | Mississippi | 39216 | — |
| University of New Mexico HSC | Albuquerque | New Mexico | 87131 | — |
| Cleveland Clinic Foundation; Dept of Endocrinology, Diabetes & Metabolism | Cleveland | Ohio | 44195 | — |
| Oklahoma University Health Science Center | Oklahoma City | Oklahoma | 73104 | — |
| Oregon Health Sciences University | Portland | Oregon | 97239 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Diabetes and Glandular Disease Clinic | San Antonio | Texas | 78229 | — |
| Endocrinology Center at North Hills, Froedtert and Medical College of Wisconsin | Menomonee Falls | Wisconsin | 53051 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00569582, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 21, 2013 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00569582 live on ClinicalTrials.gov.